# SOCS2

## Overview
The SOCS2 gene encodes the suppressor of cytokine signaling 2 protein, a critical component in the regulation of cytokine and growth factor signaling pathways. SOCS2 is part of the SOCS family, characterized by a central SH2 (Src Homology 2) domain and a SOCS box, which together facilitate its role as a negative regulator of cytokine signaling. The SH2 domain allows SOCS2 to bind phosphotyrosine residues on target proteins, while the SOCS box is involved in forming a ubiquitin ligase complex with elongin B and C, targeting proteins for degradation (Bullock2006Crystal; Linossi2021Discovery). This protein plays a pivotal role in modulating the JAK-STAT signaling pathway, influencing growth hormone signaling, and maintaining immune system balance (Haan2016SOCS2; Greenhalgh2005SOCS2). Dysregulation of SOCS2 expression or function is associated with various pathological conditions, including cancer and inflammatory diseases, highlighting its significance in cellular homeostasis and disease progression (Haan2016SOCS2; Letellier2014Identification).

## Structure
The SOCS2 protein is characterized by its central SH2 (Src Homology 2) domain, which is crucial for binding phosphotyrosine residues. This domain includes canonical structural elements such as three β-strands flanked by two α-helices, along with an additional N-terminal α-helix (ESS) unique to SOCS family proteins (Linossi2021Discovery). The SH2 domain also features an exosite that enhances binding affinity to phosphorylated ligands, with the F3 peptide binding as an α-helix between the ESS and the BC loop, stabilizing the BC loop's conformation (Linossi2021Discovery).

The SOCS2 protein also contains a SOCS box, which interacts with elongin B and elongin C, forming a complex that functions as a ubiquitin ligase (Bullock2006Crystal). The SOCS box and SH2 domain exhibit a conserved spatial arrangement, with the SOCS box contributing to substrate recognition and ubiquitination (Bullock2006Crystal). The SOCS2 structure is further defined by large EF and BG loop insertions, which influence substrate selectivity (Bullock2006Crystal).

Post-translational modifications, such as phosphorylation, play a role in SOCS2's function and interactions, particularly in its regulation of cytokine signaling pathways (Ramachandran2023Structurebased).

## Function
SOCS2 (suppressor of cytokine signaling 2) is a key regulator of cytokine and growth factor signaling, primarily through its role in the ubiquitination and degradation of target proteins. It is a component of the Cullin5 E3 ubiquitin ligase complex, acting as a substrate recognition subunit that binds to phosphotyrosine-modified epitopes, known as degrons, targeting them for ubiquitination and subsequent proteasomal degradation (Kung2019Structural). This process is crucial for regulating the JAK-STAT signaling pathway, which is involved in cytokine signaling and growth hormone (GH) pathways (Greenhalgh2005SOCS2; Kung2019Structural).

SOCS2 negatively regulates GH signaling by interacting with the GH receptor at specific phosphorylation sites, modulating GH sensitivity and preventing excessive growth (Haan2016SOCS2; Greenhalgh2005SOCS2). In healthy cells, SOCS2 acts as a negative regulator of GH-induced overgrowth by inhibiting STAT5 phosphorylation, maintaining balanced growth signaling (Haan2016SOCS2). SOCS2 is also involved in the immune system, influencing the differentiation of cells within both the innate and adaptive immune systems and regulating inflammatory responses (Haan2016SOCS2). It is active in both the cytoplasm and nucleus, modulating cellular responses to cytokines and growth factors, thereby maintaining cellular homeostasis (Haan2016SOCS2).

## Clinical Significance
The SOCS2 gene is implicated in various diseases and conditions due to mutations, altered expression levels, or changes in its interactions. In cancer, SOCS2 expression is often downregulated, which is associated with aggressive tumor progression and poor prognosis in hepatocellular carcinoma, breast cancer, and colorectal cancer (CRC) (Haan2016SOCS2; Letellier2014Identification). In CRC, low SOCS2 expression is linked to shorter disease-free survival, making it a potential early diagnostic marker (Letellier2014Identification). Conversely, high SOCS2 expression correlates with improved survival rates in breast cancer (Haan2016SOCS2).

In hematological malignancies, SOCS2 is overexpressed in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), where it is associated with poor outcomes and disease progression (Sobah2021SOCS; Keewan2021The). SOCS2 overexpression in AML is linked to high-risk cases and poor overall survival, particularly in pediatric patients (Keewan2021The).

Mutations in SOCS2, such as the R96C mutation, can lead to increased inflammatory responses. This mutation affects the SH2 domain, impairing SOCS2's ability to bind phosphorylated peptides, which results in heightened inflammation and susceptibility to infections, as observed in sheep models (GuzylackPiriou2023The; Rupp2015A).

## Interactions
SOCS2 (Suppressor of Cytokine Signaling 2) is involved in several protein interactions, primarily through its role as a component of the Cullin-RING E3 ubiquitin ligase (CRL) complex. SOCS2 interacts with Elongin B and Elongin C to form a ternary complex, which is essential for its function as an E3 ubiquitin ligase. This interaction is stabilized by Elongin B, preventing the unfolding of the SOCS2-Elongin C dimer at physiological temperatures (Gadd2015Serendipitous; Bullock2006Crystal). The SOCS box of SOCS2 is crucial for recruiting Cullin 5, forming part of the CRL complex, which targets phosphorylated hormone receptors for degradation (Gadd2015Serendipitous).

SOCS2 also binds to phosphotyrosine-modified epitopes on various receptors, including the growth hormone receptor (GHR), insulin-like growth factor-I receptor, erythropoietin receptor, leptin receptor, and epidermal growth factor receptor. These interactions occur when specific tyrosine residues on these proteins are phosphorylated, facilitating their ubiquitination and subsequent proteasomal degradation (Gadd2015Serendipitous; Kung2019Structural). The SH2 domain of SOCS2 is responsible for recognizing these phosphotyrosine substrates, and mutations in this domain can disrupt these interactions (Bullock2006Crystal).


## References


[1. (Linossi2021Discovery) Edmond M. Linossi, Kunlun Li, Gianluca Veggiani, Cyrus Tan, Farhad Dehkhoda, Colin Hockings, Dale J. Calleja, Narelle Keating, Rebecca Feltham, Andrew J. Brooks, Shawn S. Li, Sachdev S. Sidhu, Jeffrey J. Babon, Nadia J. Kershaw, and Sandra E. Nicholson. Discovery of an exosite on the socs2-sh2 domain that enhances sh2 binding to phosphorylated ligands. Nature Communications, December 2021. URL: http://dx.doi.org/10.1038/s41467-021-26983-5, doi:10.1038/s41467-021-26983-5. This article has 12 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-021-26983-5)

[2. (Rupp2015A) Rachel Rupp, Pavel Senin, Julien Sarry, Charlotte Allain, Christian Tasca, Laeticia Ligat, David Portes, Florent Woloszyn, Olivier Bouchez, Guillaume Tabouret, Mathieu Lebastard, Cécile Caubet, Gilles Foucras, and Gwenola Tosser-Klopp. A point mutation in suppressor of cytokine signalling 2 (socs2) increases the susceptibility to inflammation of the mammary gland while associated with higher body weight and size and higher milk production in a sheep model. PLOS Genetics, 11(12):e1005629, December 2015. URL: http://dx.doi.org/10.1371/journal.pgen.1005629, doi:10.1371/journal.pgen.1005629. This article has 71 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1005629)

3. (GuzylackPiriou2023The) The loss-of-function of SOCS2 increases the inflammatory response toStaphylococcus aureusinfection. This article has 1 citations.

[4. (Sobah2021SOCS) Mohamed Luban Sobah, Clifford Liongue, and Alister C. Ward. Socs proteins in immunity, inflammatory diseases, and immune-related cancer. Frontiers in Medicine, September 2021. URL: http://dx.doi.org/10.3389/fmed.2021.727987, doi:10.3389/fmed.2021.727987. This article has 82 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmed.2021.727987)

[5. (Letellier2014Identification) E Letellier, M Schmitz, K Baig, N Beaume, C Schwartz, S Frasquilho, L Antunes, N Marcon, P V Nazarov, L Vallar, J Even, and S Haan. Identification of socs2 and socs6 as biomarkers in human colorectal cancer. British Journal of Cancer, 111(4):726–735, July 2014. URL: http://dx.doi.org/10.1038/bjc.2014.377, doi:10.1038/bjc.2014.377. This article has 49 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/bjc.2014.377)

[6. (Greenhalgh2005SOCS2) Christopher J. Greenhalgh, Elizabeth Rico-Bautista, Mattias Lorentzon, Anne L. Thaus, Phillip O. Morgan, Tracy A. Willson, Panagiota Zervoudakis, Donald Metcalf, Ian Street, Nicos A. Nicola, Andrew D. Nash, Louis J. Fabri, Gunnar Norstedt, Claes Ohlsson, Amilcar Flores-Morales, Warren S. Alexander, and Douglas J. Hilton. Socs2 negatively regulates growth hormone action in vitro and in vivo. Journal of Clinical Investigation, 115(2):397–406, February 2005. URL: http://dx.doi.org/10.1172/jci22710, doi:10.1172/jci22710. This article has 6 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci22710)

[7. (Haan2016SOCS2) Serge Haan. Socs2 physiological and pathological functions. Frontiers in Bioscience, 8(1):189–204, 2016. URL: http://dx.doi.org/10.2741/E760, doi:10.2741/e760. This article has 92 citations and is from a peer-reviewed journal.](https://doi.org/10.2741/E760)

[8. (Keewan2021The) Esra’a Keewan and Ksenia Matlawska-Wasowska. The emerging role of suppressors of cytokine signaling (socs) in the development and progression of leukemia. Cancers, 13(16):4000, August 2021. URL: http://dx.doi.org/10.3390/cancers13164000, doi:10.3390/cancers13164000. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13164000)

[9. (Gadd2015Serendipitous) Morgan S. Gadd, Emil Bulatov, and Alessio Ciulli. Serendipitous sad solution for dmso-soaked socs2-elonginc-elonginb crystals using covalently incorporated dimethylarsenic: insights into substrate receptor conformational flexibility in cullin ring ligases. PLOS ONE, 10(6):e0131218, June 2015. URL: http://dx.doi.org/10.1371/journal.pone.0131218, doi:10.1371/journal.pone.0131218. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0131218)

[10. (Ramachandran2023Structurebased) Sarath Ramachandran, Nikolai Makukhin, Kevin Haubrich, Manjula Nagala, Beth Forrester, Dylan M. Lynch, Ryan Casement, Andrea Testa, Elvira Bruno, Rosaria Gitto, and Alessio Ciulli. Structure-based design of a phosphotyrosine-masked covalent ligand targeting the e3 ligase socs2. Nature Communications, October 2023. URL: http://dx.doi.org/10.1038/s41467-023-41894-3, doi:10.1038/s41467-023-41894-3. This article has 9 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-41894-3)

[11. (Bullock2006Crystal) Alex N. Bullock, Judit É. Debreczeni, Aled M. Edwards, Michael Sundström, and Stefan Knapp. Crystal structure of the socs2–elongin c–elongin b complex defines a prototypical socs box ubiquitin ligase. Proceedings of the National Academy of Sciences, 103(20):7637–7642, May 2006. URL: http://dx.doi.org/10.1073/pnas.0601638103, doi:10.1073/pnas.0601638103. This article has 139 citations.](https://doi.org/10.1073/pnas.0601638103)

[12. (Kung2019Structural) Wei-Wei Kung, Sarath Ramachandran, Nikolai Makukhin, Elvira Bruno, and Alessio Ciulli. Structural insights into substrate recognition by the socs2 e3 ubiquitin ligase. Nature Communications, June 2019. URL: http://dx.doi.org/10.1038/s41467-019-10190-4, doi:10.1038/s41467-019-10190-4. This article has 23 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-019-10190-4)